Trial Profile

Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients With High-Risk Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Regorafenib (Primary)
Indications Liver cancer
Focus Therapeutic Use

Most Recent Events

24 Jan 2025 Planned primary completion date changed from 5 Dec 2024 to 5 Dec 2025.
15 Aug 2023 Status changed from not yet recruiting to recruiting.
14 Jun 2023 Planned number of patients changed from 27 to 30.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com